Serotherapy of L1210 murine leukaemia--reasons for ineffectiveness of in vivo treatment by L.1 monoclonal antibody.

A monoclonal antibody (L.1), reacting in vitro specifically with L1210 leukaemia cells in a complement-dependent cytotoxicity assay (CDC), has been exploited for serotherapy studies. Different regiments of L.1 treatment of CD2F1 mice bearing the semi-syngeneic L1210 leukaemia did not prolong the lif...

Descripción completa

Detalles Bibliográficos
Autores principales: Testorelli, C., Canti, G., Franco, P., Goldin, A., Nicolin, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1983
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011306/
https://www.ncbi.nlm.nih.gov/pubmed/6830686

Ejemplares similares

Ejemplares similares